Innate Pharma Past Earnings Performance
Past criteria checks 0/6
Innate Pharma's earnings have been declining at an average annual rate of -26.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 16.7% per year.
Key information
-26.4%
Earnings growth rate
-26.3%
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | -16.7% |
| Return on equity | -118.3% |
| Net Margin | -100.8% |
| Next Earnings Update | 27 Mar 2025 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Dec 20
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
Oct 24Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
May 21Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 24Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Sep 30Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 16Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Mar 30Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic
Dec 18Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year
Aug 04Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
May 12Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
Apr 13Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook
Mar 26Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?
Nov 11Revenue & Expenses Breakdown
How Innate Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 34 | -34 | 19 | 0 |
| 31 Mar 24 | 48 | -21 | 19 | 0 |
| 31 Dec 23 | 62 | -8 | 18 | 0 |
| 30 Sep 23 | 57 | -35 | 19 | 0 |
| 30 Jun 23 | 52 | -63 | 19 | 0 |
| 31 Mar 23 | 55 | -60 | 21 | 0 |
| 31 Dec 22 | 58 | -58 | 22 | 0 |
| 30 Sep 22 | 57 | -40 | 24 | 0 |
| 30 Jun 22 | 57 | -22 | 25 | 0 |
| 31 Mar 22 | 41 | -34 | 25 | 0 |
| 31 Dec 21 | 25 | -45 | 26 | 0 |
| 30 Jun 21 | 46 | -8 | 17 | 0 |
| 31 Mar 21 | 58 | -4 | 18 | 0 |
| 31 Dec 20 | 70 | -1 | 19 | 0 |
| 30 Sep 20 | 67 | -54 | 31 | 0 |
| 30 Jun 20 | 63 | -44 | 31 | 0 |
| 31 Mar 20 | 75 | -33 | 28 | 0 |
| 31 Dec 19 | 85 | 8 | 21 | 0 |
| 30 Sep 19 | 108 | 5 | 24 | 0 |
| 30 Jun 19 | 130 | 31 | 22 | 0 |
| 31 Mar 19 | 112 | 17 | 20 | 0 |
| 31 Dec 18 | 94 | 3 | 18 | 0 |
| 30 Sep 18 | 70 | -19 | 16 | 0 |
| 30 Jun 18 | 46 | -40 | 15 | 0 |
| 31 Mar 18 | 45 | -44 | 16 | 0 |
| 31 Dec 17 | 44 | -48 | 17 | 0 |
| 30 Sep 17 | 55 | -28 | 16 | 0 |
| 30 Jun 17 | 66 | -8 | 14 | 0 |
| 31 Mar 17 | 66 | 3 | 12 | 0 |
| 31 Dec 16 | 66 | 13 | 10 | 0 |
| 30 Sep 16 | 53 | 5 | 8 | 0 |
| 30 Jun 16 | 41 | -2 | 7 | 0 |
| 31 Mar 16 | 33 | -4 | 6 | 0 |
| 31 Dec 15 | 25 | -7 | 6 | 0 |
| 30 Sep 15 | 17 | -13 | 5 | 0 |
| 30 Jun 15 | 8 | -19 | 4 | 0 |
| 31 Mar 15 | 8 | -19 | 4 | 0 |
| 31 Dec 14 | 8 | -20 | 5 | 0 |
| 30 Sep 14 | 11 | -15 | 6 | 0 |
| 30 Jun 14 | 14 | -10 | 8 | 0 |
| 31 Mar 14 | 15 | -6 | 8 | 0 |
Quality Earnings: IPH is currently unprofitable.
Growing Profit Margin: IPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IPH is unprofitable, and losses have increased over the past 5 years at a rate of 26.4% per year.
Accelerating Growth: Unable to compare IPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: IPH has a negative Return on Equity (-118.25%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/27 01:59 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Innate Pharma S.A. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| Yigal Nochomovitz | Citigroup Inc |
| Michael Thomas Cooper | Edison Investment Research |